MaxCyte Change In Cash from 2010 to 2024

MXCT Stock  USD 4.28  0.06  1.38%   
MaxCyte Change In Cash yearly trend continues to be comparatively stable with very little volatility. Change In Cash is likely to outpace its year average in 2024. From the period from 2010 to 2024, MaxCyte Change In Cash quarterly data regression had mean square error of 331.5 T and mean deviation of  13,059,244. View All Fundamentals
 
Change In Cash  
First Reported
2010-12-31
Previous Quarter
35.4 M
Current Value
37.2 M
Quarterly Volatility
18.7 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 4.4 M, Interest Expense of 138.6 K or Selling General Administrative of 31.6 M, as well as many indicators such as Price To Sales Ratio of 11.17, Dividend Yield of 0.0 or PTB Ratio of 2.2. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
  
Check out the analysis of MaxCyte Correlation against competitors.
For more information on how to buy MaxCyte Stock please use our How to Invest in MaxCyte guide.

Latest MaxCyte's Change In Cash Growth Pattern

Below is the plot of the Change In Cash of MaxCyte over the last few years. It is MaxCyte's Change In Cash historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
Change In Cash10 Years Trend
Slightly volatile
   Change In Cash   
       Timeline  

MaxCyte Change In Cash Regression Statistics

Arithmetic Mean5,333,343
Coefficient Of Variation351.29
Mean Deviation13,059,244
Median2,644,100
Standard Deviation18,735,340
Sample Variance351T
Range73.9M
R-Value0.35
Mean Square Error331.5T
R-Squared0.12
Significance0.20
Slope1,468,873
Total Sum of Squares4914.2T

MaxCyte Change In Cash History

202437.2 M
202335.4 M
2022-36.7 M
202129 M
20203.5 M
2019M
2018-14.1 M

About MaxCyte Financial Statements

MaxCyte shareholders use historical fundamental indicators, such as Change In Cash, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Change In Cash35.4 M37.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for MaxCyte Stock Analysis

When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.